Thirteen years of regional growth through collaboration, networking and innovation support

Since the start 2003, Uppsala has been working to stimulate growth in the life science sector.

Together with the universities, companies, healthcare, and society we strive to increase the sector’s international competitiveness. Below you see some examples of how we do it:

2017

A new international evaluation of Uppsala BIO shows that it has “successfully mobilised all the key actors across the three institutional spheres of the Triple Helix constellation and that Uppsala BIO has formulated a well-defined and clear strategy for the future”.

2016

GE Healthcare Life Sciences signs a two-year collaboration agreement with Uppsala BIO. The goal is to evaluate innovative tools and technologies that support the future manufacture of biopharmaceuticals.

Discussions with regional stakeholders on continued and increased funding result in new output efficiency with an even clearer focus on growth.

The Uppsala BIO Board is replaced by a steering committee with Christina Frimodig, STUNS CEO, as its first chairperson.

2015

Uppsala BIO continues to take great responsibility in building the strategic innovation programme Swelife (approved in 2014). Uppsala BIO employees participated in Swelife’s board work, acted as programme leaders within the program office, as national project manager for Swelife’s calls, and as the coordinator in East Middle Sweden / Uppsala. Uppsala BIO has also appointed and coordinated expert panels in Swelife’s Hands-on programmes. The hands-on model is built on BIO-X methodology and Uppsala BIO-personnel has been instrumental in implementing this in Swelife calls.

2014

BIO-X Forum replaces Uppsala Research Forum and a number of BIO-X projects talk about their plans. Statistics show that additional investments for previous BIO-X projects amount to 6.5-fold the amount initially contributed by BIO-X.

The Industrial Partnership initiative starts. Its goal is to help companies find external collaboration partners.

Diagnostic Forum attracts 200 participants to Uppsala to discuss improved diagnostics, e.g. new markers and analytical methods, for cancer and Alzheimer’s disease.

Uppsala BIO contributes to getting the Uppsala Health Summit up and running. The first conference takes place on June 3-4.

2013

Uppsala BIO’s ten-year Vinnova ‘Vinnväxt’ (win-growth) period evolves into an ‘Uppväxlings’ (gearing-up) phase. Greater national and international focus is required.

Vinnova granted 2013-2016 also Uppsala BIO 30 MSEK for the project ‘National rollout of BIO-X’. The dissemination of BIO-X was initiated through a series of national calls for proposals. Within the scope of the project, the planned so-called request-for-financing model, i.e. an interface between the BIO-X programme and the national administrative authority Vinnova, was developed and tested.

Uppsala BIO organises Diagnostic Forum that replace BIO Ångström and attracts 200 national and international participants from seven countries to Uppsala to discuss improved diagnostics, e.g. new markers and analytical methods, as well as health economics for cancer and Alzheimer’s disease.

Uppsala BIO and a number of companies from Uppsala attend the first Nordic partnering conference NLSDays and coordinate a joint booth for the Stockholm-Uppsala region.

2011

Uppsala BIO is responsible for a benchmarking study on how various European innovation support schemes work within the framework of FP 7 Project TERM – Tissue Engineering and Regenerative Medicine. The project includes developing a proposal for how innovation support could be designed to enable several countries / regions to collaborate in early innovation.

Roche signs its first European strategic cooperation agreement with Uppsala BIO.

Uppsala BIO participates in the programme leading to a Certified College of Technology in Uppsala, Tierp and Östhammar.

Uppsala BIO initiates collaboration with One Nucleus, the international membership organisation for life science and healthcare companies, based in Cambridge, UK. Among other things, this generates a number of events at the BIO International Convention in San Diego.

UK Links is started to stimulate interest in the UK as a market for the region’s life science companies.

Business region Göteborg, later Sahlgrenska Science Park, is testing the BIO-X process in calls 2012-2014.

2010

The BIO-X programme is re-launched.

The new network forum ‘Efter Jobbet’ is launched to focus on issues narrower than those generally debated in the more broad-based BIO-PUBs.

The BIO Kompetens Forum starts to chart and address skills shortages identified by the life science industry and Uppsala BIO members.

Thanks to support from the EU’s Regional Development Funds, companies and projects in East Middle Sweden, as well as Stockholm, can for the first time apply to BIO-X.

Uppsala BIO’s project ‘The Innovative Hospital’ was granted funding over three years to open the Innovation Akademiska initiative to companies wanting to develop products in close collaboration with healthcare as an end-user, as well as to hospital staff with ideas emanating from their day-to-day work. 

2009

An international evaluation led by Vinnova unequivocally confirms Uppsala BIO’s key role as a cluster facilitator in the strong life science environment that the region represents.

Uppsala Research Forum is held for the first time. BIO-X projects met Uppsala BIO member companies.

The project Global Links started 2009 and the goal was to support life science start-ups in international commercialisation to accelerate revenue creation.

2008

Erik Forsberg is appointed Uppsala BIO’s new Managing Director.

Uppsala University Hospital launches a project to stimulate new innovations for better nursing and medical care. Its activities, later known as ‘Innovation Akademiska’, are run as a project led by Uppsala BIO. Almi Business Partner is also part of the project team.

2007

The collaboration Stockholm-Uppsala Life Science (SULS), the first joint effort with Stockholm to actively market the region’s life science outside of Sweden, starts.

2006

Lars Hagel is appointed Chairman of the Board. Uppsala BIO joins CEBR, a membership-driven network of life science clusters across Europe.

2005

Jonas Åström is appointed Managing Director. The first BIO-Ångström was conducted, a meeting place and an interdisciplinary forum for academia and companies with the goal of generating new ideas and new collaborations.

2004

The BIO-X programme, which provided an entirely new platform for taking ideas and research findings to proof of concept, is launched.

The first BIO-PUB is organised together with Connect Uppsala. These network meetings, based on the concept of Partnership University-Business, will make it easier for participants to establish contacts outside their own organisation.

Uppsala BIO is active in the restart of Uppsala Business Center, now renamed Uppsala Innovation Centre, and is one of the main financiers.

2003

Uppsala BIO begins life as one of three winners in the first Vinnväxt call. Vinnväxt is a ten-year programme promoting sustainable growth by developing internationally competitive research and innovation environments in specific growth fields.

Ingvar Wiberger is the first Managing Director and the goal for Uppsala BIO is that the region should become ‘internationally competitive within life science’.

About us

Erik Forsberg. Ph.D., Associate Professor, CEO. “My goal is to drive system improvements that create better conditions for life science to develop in Uppsala.”

Contact me

Kristin Hellman. M.Sc., Project Manager. “I focus on facilitating interaction between large companies and small start-ups and academic projects in order to accelerate the development of promising new products and technologies.”

Contact me